Stockreport

Werewolf Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]

Werewolf Therapeutics, Inc.  (HOWL) 
PDF – Encouraging signs of clinical activity at tolerable doses disclosed from ongoing Phase 1 clinical trial of WTX-330 – – Updated data on WTX-124 in combination with p [Read more]